As previously disclosed, Celldex will issue a press release in concordance with the presentation on November 24 and will host a conference call to review the data on Monday, November 25 at 8:30 am ET.
everyone will want in.
New York Times
Imbruvica, Drug to Treat Blood Cancer, Gains F.D.A. Approval
By ANDREW POLLACK
Published: November 13, 2013
Wall Street analysts have projected sales of several billion dollars a year for Imbruvica, which is known generically as ibrutinib. The F.D.A. had designated Imbruvica a “breakthrough therapy” for three types of cancer under a program established by Congress last year. That designation contributed to the drug’s approval more than three months before the F.D.A.’s deadline in late February.
There was some concern among investors that the drug was not approved for C.L.L. on Wednesday.Executives at Pharmacyclics and Johnson & Johnson said the F.D.A. was continuing to evaluate that application
Yahoo Finance Insider Transactions- Last Week inside Buys
Nov 29, 2013 SINSKEY ANTHONY JDirector 3,800 Direct Purchase at $3.92 per share. 14,896
Nov 29, 2013 MCCLEMENTS WILLIAM M.Officer 1,000 Direct Purchase at $3.91 per share. 3,910
Nov 29, 2013 PORTER MICHAEL EDirector 25,000 Direct Purchase at $3.79 per share. 94,750
Nov 27, 2013 PORTER MICHAEL EDirector 50,000 Direct Purchase at $3.51 per share. 175,500
Nov 27, 2013 MCCLEMENTS WILLIAM M.Officer 6,000 Direct Purchase at $3.56 per share. 21,360Nov 27, 2013 CROCKER GARY LDirector 207,000 Indirect Purchase at $3.71 - $3.74 per share. 771,0002
Seeking Alpha Market Currents 9/12/13
Facebook price target hiked at JPMorgan, CLSA
Expecting strong advertising traction to build into the end of the year, JPMorgan reiterates its Buy rating on Facebook (FB) and ups the price target to $53 from $44. The team is raising its mobile and desktop estimates, and projects mobile will surpass 50% of total ad revenues in Q4.
CLSA one-ups JPMorgan, hiking its price target to a Street-high $60. Traffic is still under-monetized with several "goldmine" opportunities yet to be unlocked - video ads, games, search, ad network, and Instagram, to name a few. The valuation could reach $97 over time, says CLSA.
Why Facebook is Better Than Twitter
BY Chris Ciaccia | 11/20/13 -
BY Chris Ciaccia | 12/02/13 - 05:31 PM EST
Wall Street 9/26/13 By: Emily Coyle
Facebook Inc. (NASDAQ:FB) had a story to “Like” Thursday after its stock surged, topping $50 per share for the first time thanks to increased confidence from Goldman Sachs (NYSE:GS). MarketWatch reports that the firm upped its price target from $52 to $58 and cited the social network’s presentation at AdWeek 2013 in New York for its newfound support. Analyst Heather Bellini explained in a note to investors, “Our
conversations on the conference floor suggest continuing momentum for Facebook, and but also significant runway left.”
Analysts: Facebook a Buy
Katey Troutman | More Articles
Page 1 of 4
Facebook (NASDAQ:FB): BMO Capital expects analysts to raise their estimates for Facebook’s stock as investors further digest the company’s opportunities in social TV and second-screen behavior. The firmrecommends buying the stock ahead of the company’s results and keeps an Outperform rating on the shares
Yahoo Finance The Daily Ticker 10/29/13
By: Stock Whisper 11/25/13
Article :Celldex Will Not Stop Here
The positive trial data of ReACT study is an encouraging event in the therapeutic area of recurring glioblastoma. Currently, there are limited treatment options available for the indication, with the patients having very low survival rates. If and when the vaccine is approved it could provide a breakthrough for not only Celldex but also for immunotherapy. Additionally, the Genentech's vaccine Avastin was approved on accelerated basis because of its objective response rates. If the response rates of rindopepimut reported continue in the final data the vaccine may also be approved on an accelerated basis, owing to absence of viable treatment for glioblastoma patients.
The share prices of the company are currently witnessing an upward momentum and are expected to continue the trend. The company is expected to release data for its experimental drug CDX-1135 for dense deposit disease, in February 2014 conference call. Furthermore, the study CDX-301 for hematopoietic stem cell transplant (HSCT) is also expected to initiate in early 2014.
The company holds promise and the investor sentiment is also positive and is expected to reach it mean price target of $36.89 over the next few months. The analyst recommendation is a Buy. Overall, the stock is a sound investment and has major potential over the long run.
Here's DD For Data Coming Out.
Keep Your Eyes on Celldex
By Keith Speights | More Articles
November 11, 2013 | Comments (0)
Investors are also intensely interested in results related to Celldex's lead drug, Rindopepimut. The company is scheduled to discuss data from a phase 2 study of its cancer vaccine in combination with Roche's Avastinat the World Federation of Neuro-Oncology meeting on Nov. 24. A phase 3 study ofRindopepimut is also under way in combination with Merck's Temodar in treating EGFRv3-positive glioblastoma
All across the China-related media today is a story from South China Morning Post that the new Shanghai Free Trade Zone will allow users to access banned western social media platforms Facebook (FB) and Twitter, and allow foreign telecoms to operate there:
Beijing has made the landmark decision to lift a ban on internet access within the Shanghai Free-trade Zone to foreign websites considered politically sensitive by the Chinese government, including Facebook, Twitter
Business Insider 10/20/13
Evercore analysts believe Facebook's Q3 2013 revenues will come in stronger than expected from existing clients, the pair believe, based on their check of Facebook advertisers.
Survey Finds 51% of Brands Prefer Advertising on Facebook image
Quite simply, brands prefer Facebook because it is by far the most populated social network. As of March of this year Facebook has claimed 1.1 billion active users worldwide. Among the largest markets, according to Socialbakers’ statistics, over 78% of Internet users in the United States are on Facebook, with 68% in the United Kingdom, and almost 76% in Australia. A social network of this magnitude produces connections between brands and fans, and friends of fans that were previously impossible to notice.
According to a recent survey conducted by Socialbakers, of the four of the biggest social networks Facebooktrumps Twitter, LinkedIn and YouTube. But there are reasons besides population size that make Facebook an exciting place for advertisers